By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI Boston September 2023, 52 life science and healthcare startups participated in the Innovator’s Pitch Challenge (IPC), a unique pitching opportunity for early-stage companies in therapeutics, medical device, diagnostics, digital health, and R&D/services sectors, all finalist companies pitched in front of a judging panel and exhibited a poster showcasing their technology in the exhibit hall. The RESI Team would like to thank every IPC company for their hard work in preparing these presentations. We hope to continue the IPC as a unique platform for innovators and investors to connect, and we look forward to meeting and highlighting other innovative companies at future conferences.
Life Science Nation is pleased to share the winners of IPC who received the most votes during the conference, winners will receive complimentary RESI tickets valued up to 12K for the future RESI conference. Congratulations to the winners! Check them out below and see the full list of finalists here.
1st Place – Light Line Medical
Light Line Medical is solving one of the greatest causes of morbidity and high cost in medicine today – infection from invasive catheters (dialysis, urinary, ventilators and vascular). These infections are life-threatening and difficult to treat complications, particularly from antibiotic resistant microbes which are the third leading cause of death worldwide. Light Line Medical is the first to use visible light to disinfect catheters via a patented light delivery system that uniformly irradiates the internal and external surfaces of an indwelling catheter. This prevents infections long term, is safe for human tissue, does not degrade catheter materials, and has no antibiotic resistance issues. Light Line Medical has a robust patent portfolio to commercialize its visible light technology (30 issued, 19 pending, FTOs), has conclusive animal & in vitro data demonstrating the antimicrobial efficacy of its technology, and has won several awards (AMA, NASA, USPTO, etc.).
Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN | Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN| Kari Haab, Executive Director of Quality and Operations, Light Line Medical | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
2nd Place – ABLE Labs
ABLE Labs is a pioneering biotech firm headquartered in Korea, committed to democratizing the bio-research landscape with groundbreaking automation solutions. At the heart of our mission is Notable, our flagship Liquid Handling Robot, designed to bring precision and efficiency to every bio-laboratory. Challenging the status quo, ABLE Labs seeks to make automation accessible beyond just elite institutions, ensuring even smaller laboratories can harness the power of state-of-the-art technology. Drawing parallels to the early vision of Opentrons, our approach is rooted in affordability without compromising on quality or performance. As we navigate the evolving demands of bio-research, ABLE Labs remains steadfast in its commitment to enhancing lab processes, reducing human error, and accelerating scientific discoveries. Our ambition doesn’t just stop at hardware; we’re innovating at the intersection of software and biology, ensuring seamless integration and intuitive user experience. Join us as we reshape the future of bio-laboratory operations.
Sang Shin, CEO & Co-Founder, ABLE Labs | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Karen Deyo, VP of Product, Israel BD, LSN
3rd Place – Gliachem
Gliachem is a pre-clinical (pre-incorporation) stage drug development company focused on small molecule therapeutics for the treatment of rare pediatric and neurodegenerative indications. Our lead program is developing a novel drug targeting a novel target, the TRPM2 calcium ion channel, associated with Rett Syndrome (a rare pediatric disease with limited treatment options) and other neurodegenerative disorders. This is a first-in-class neurology drug program, with a unique mechanism of action. We have developed three distinct chemical series encompassing novel chemical entities (NCEs) targeting TRPM2, each of which demonstrate potency, target selectivity, and drug-like characteristics. The first clinical indication for our lead program is Rett Syndrome, for which we anticipate being in clinical trials in approximately 4 years. Regulatory incentives for Rett Syndrome enable the de-risking of our lead program for other, larger market, neurological indications, such as neuropathic pain, ischemic stroke, behavioral & neurodegenerative disorders.
Vanessa Williamson, CEO, Gliachem | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Antoinette Lowre, Manager of Business Development, LSN
LSN’s flagship RESI conference returns to the Marine’s Memorial Club & Hotel in San Francisco on January 9, 2024, followed by two days of virtual partnering for the annual healthcare conference week. Want to be part of RESI JPM 2024? Register now to save $600 on super early bird rates by October 20. RESI also provides sponsorship and exhibition opportunities to help you increase your brand visibility at RESI Boston June or any future RESI conferences, contact us to learn more.
Next Phase Newsletter 
Leave a comment